木下 真理子 (キノシタ マリコ)

KINOSHITA Mariko

写真a

所属

医学部 医学科 発達泌尿生殖医学講座小児科学分野

職名

特別准教授

外部リンク

学位 【 表示 / 非表示

  • 学士(医学) ( 2005年3月   宮崎大学 )

 

論文 【 表示 / 非表示

  • Successful treatment of paraspinal/spinal epidural lymphoma by early intervention and local control with proton beam therapy

    Nagasawa S., Yamada A., Kinoshita M., Kamimura S., Moritake H.

    Pediatrics international : official journal of the Japan Pediatric Society   64 ( 1 )   e14970   2022年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Pediatrics international : official journal of the Japan Pediatric Society  

    DOI: 10.1111/ped.14970

    Scopus

    PubMed

  • Successful treatment with rituximab for autoimmune cytopenia after autologous hematopoietic stem cell transplantation

    Kinoshita M., Yamada A., Saito Y., Kamimura S., Moritake H.

    Pediatrics international : official journal of the Japan Pediatric Society   64 ( 1 )   e14975   2022年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Pediatrics international : official journal of the Japan Pediatric Society  

    DOI: 10.1111/ped.14975

    Scopus

    PubMed

  • Development and validation of an HPLC method for analysis of topotecan in human cerebrospinal fluid and its application in elimination evaluation of topotecan after intraventricular injection

    Yoshikawa N., Yamada A., Yokota T., Yamada Y., Kinoshita M., Moritake H., Ikeda R.

    Cancers   13 ( 18 )   2021年9月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancers  

    Intrathecal administration of anticancer drugs is an effective dosage strategy, but the elimination of intraventricular drugs is not uniform in all patients. For safety, a system to evaluate local pharmacokinetics in the ventricles after administration is desired. In this study, we developed a simple and reproducible method to measure topotecan concentration in the cerebrospinal fluid (CSF) and confirmed its clinical applicability. High-performance liquid chromatography (HPLC) analysis was performed using a C18 column to measure the total topotecan concentration in the CSF. Clinical CSF samples were obtained from a 1-year old child with poor CSF absorption and stagnation. The patient received topotecan via an intraventricular subcutaneous reservoir. The HPLC method complied with the validation criteria. The lower limit of quantitation of this method was 0.04 µM. Using the developed method, we could determine the difference in topotecan CSF concentrations at 24 and 48 h after administration. The patient’s topotecan elimination rate was extremely low, and signs of adverse effects were observed at high CSF concentration of topotecan. The developed method could detect the delay in topotecan elimination after intrathecal injection. The findings of this study are valuable for the development of personalized treatments for the intrathecal administration of anticancer drugs.

    DOI: 10.3390/cancers13184643

    Scopus

    PubMed

  • パゾパニブが有効性を示した多発肺転移を有する難治性Ewing肉腫

    横山 亮平, 山田 愛, 木下 真理子, 澤 大介, 齋藤 祐介, 上村 幸代, 盛武 浩

    日本小児血液・がん学会雑誌   58 ( 1 )   40 - 44   2021年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:日本小児血液・がん学会  

    <p>Ewing肉腫(ES)は骨または軟部組織から発生する悪性腫瘍で,小児や若年成人に好発する.限局例では70%の無病生存が期待できるが,転移例や標準的化学療法抵抗例の予後は極めて不良である.症例は19歳男性.右腸骨腫瘍の生検組織より<i>EWSR1-FLI1</i>融合遺伝子を検出し,ESと診断した.胸部CTで多発肺転移を認め,ビンクリスチン,ドキソルビシン,シクロフォスファミド,イフォスファミド,エトポシドを用いたVDC/IE療法,原発部への放射線照射,ブスルファンとメルファランによる自家末梢血幹細胞移植併用大量化学療法,さらに複数の化学療法を施行するも非寛解であった.その後,パゾパニブ内服を開始し縮小効果を認め,7か月間の延命が可能であった.パゾパニブは経口薬のため在宅管理が可能で,さらに近年では長期生存例の報告も散見され,難治性ESの治療において考慮すべき薬剤と思われる.</p>

    DOI: 10.11412/jspho.58.40

    CiNii Research

  • Mannose and phosphomannose isomerase regulate energy metabolism under glucose starvation in leukemia

    Saito Y., Kinoshita M., Yamada A., Kawano S., Liu H.S., Kamimura S., Nakagawa M., Nagasawa S., Taguchi T., Yamada S., Moritake H.

    Cancer Science   112 ( 12 )   4944 - 4956   2021年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Science  

    Diverse metabolic changes are induced by various driver oncogenes during the onset and progression of leukemia. By upregulating glycolysis, cancer cells acquire a proliferative advantage over normal hematopoietic cells; in addition, these changes in energy metabolism contribute to anticancer drug resistance. Because leukemia cells proliferate by consuming glucose as an energy source, an alternative nutrient source is essential when glucose levels in bone marrow are insufficient. We profiled sugar metabolism in leukemia cells and found that mannose is an energy source for glycolysis, the tricarboxylic acid (TCA) cycle, and the pentose phosphate pathway. Leukemia cells express high levels of phosphomannose isomerase (PMI), which mobilizes mannose to glycolysis; consequently, even mannose in the blood can be used as an energy source for glycolysis. Conversely, suppression of PMI expression or a mannose load exceeding the processing capacity of PMI inhibited transcription of genes related to mitochondrial metabolism and the TCA cycle, therefore suppressing the growth of leukemia cells. High PMI expression was also a poor prognostic factor for acute myeloid leukemia. Our findings reveal a new mechanism for glucose starvation resistance in leukemia. Furthermore, the combination of PMI suppression and mannose loading has potential as a novel treatment for driver oncogene-independent leukemia.

    DOI: 10.1111/cas.15138

    Scopus

    PubMed

全件表示 >>

MISC 【 表示 / 非表示

受託研究受入実績 【 表示 / 非表示

  • デファイテリオ静注200mg一般使用成績調査

    2021年02月 - 2025年08月

    日本新薬株式会社 

     詳細を見る

    担当区分:研究代表者